Paxmedica submits clinical trial request in autism spectrum disorder

Tarrytown, ny, june 14, 2023 (globe newswire) -- via newmediawire – paxmedica, inc. (nasdaq: pxmd), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (apt) for the treatment of autism spectrum disorder (asd) and other serious conditions with intractable neurologic symptoms, today announced that it has submitted a request to the south african health products regulatory authority (sahpra), seeking approval to conduct a double-blind, placebo-controlled study, pax-asd-101.  this trial will seek to enroll a total of 30 subjects with confirmed asd, ages 4 to 18, at multiple sites in south africa.  this is the first new clinical trial on the safety, tolerability, and efficacy of suramin since the company announced the results of its prior phase ii trial in 2021. enrollment is expected to begin in q4 2023, following sahpra's potential approval later this summer.
PXMD Ratings Summary
PXMD Quant Ranking